CrushSCI.com
71Average days
66Median days
25Fastest days
160Longest days
1012025 publications

Paper Review Records

All Paper Review Records

16 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

25 days

Comparative efficacy of CLDN18.2-directed regimens in advanced gastric/gastroesophageal junction adenocarcinoma: a meta-analysis of single-arm trials

Authors
Yue Yuan; Hongkai Yan; Qinhang WuShow moreShow less
Affiliations
1. School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, ChinaShow moreShow less
Source PDF DOI Publisher page
27 days

Effector-to-target ratio as a translational bottleneck for CD33 T-cell engagers in acute myeloid leukemia: a quantitative reanalysis of AMG 330

Authors
Hamid BelloutShow moreShow less
Affiliations
1. Northern Illinois University, DeKalb, USAShow moreShow less
Source PDF DOI Publisher page
89 days

Preclinical evaluation and mechanistic analysis of antitumor effects of the novel anti-CD147 antibody DS-1471a in liver cancer models

Authors
Hiroshi Yuita; Sadanori Watanabe; Jun Tsukada; Yoshikazu Johmura; Sae Aratani; Hirokazu Ishikawa; Ryuichi Nakamura; Miki Yokoyama; Mari Hashimoto; Hideo Yukinaga; Huynh The Hung; Makoto Nakanishi; Keisuke FukuchiShow moreShow less
Affiliations
1. Translational Science Department II, Daiichi Sankyo Co., Ltd., Tokyo, Japan; 2. Discovery Research Laboratories I, Daiichi Sankyo Co., Ltd., Tokyo, Japan; 3. Division of Cancer and Senescence Biology, Cancer Research Institute, Institute for Frontier Science Initiative, Kanazawa University, Kanazawa, Japan; 4. Division of Cancer Cell Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; 5. Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan; 6. Translational Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan; 7. Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan; 8. Daiichi Sankyo Inc., Basking Ridge, USA; 9. Division of Cellular and Molecular Research, National Cancer Centre, Singapore, SingaporeShow moreShow less
Source PDF DOI Publisher page
76 days

A phase 1 study of PF-07260437, a B7-H4 × CD3 bispecific T-cell engager, in patients with advanced or metastatic breast, ovarian, and endometrial cancer

Authors
Fengting Yan; Marcia Cruz-Correa; Jennifer Specht; Edward Wenge Wang; Jinyu Lu; Hatem Soliman; Amy Jackson-Fisher; Szu-Yu Tang; Sibo Jiang; Christophe Le Corre; Meng Li; David SommerhalderShow moreShow less
Affiliations
1. Swedish Cancer Institute, Seattle, USA; 2. Pan American Center for Oncology Trials, San Juan, USA; 3. Fred Hutchinson Cancer Center, Seattle, USA; 4. City of Hope Comprehensive Cancer Center, Duarte, USA; 5. Montefiore Einstein Comprehensive Cancer Center, Bronx, USA; 6. Moffitt Cancer Center, Tampa, USA; 7. Pfizer, San Diego, USA; 8. Pfizer, South San Francisco, USA; 9. NEXT Oncology, San Antonio, USAShow moreShow less
Source PDF DOI Publisher page
136 days

Preclinical and clinical evaluation of futibatinib in combination with binimetinib in patients with advanced cancer

Authors
Jordi Rodon; Bert O’Neil; Christopher Lim; Natraj R. Ammakkanavar; Carlos Torrado; Kazuaki Matsuoka; Hiroshi Hirai; Akihiro Miura; Bailey Anderson; Leah Jin; Nanae Hangai; Amanda Long; Volker Wacheck; Lee RosenShow moreShow less
Affiliations
1. MD Anderson Cancer Center, Houston, USA; 2. Community Health Network, Indianapolis, USA; 3. Division of Hematology-Oncology, UCLA, Los Angeles, USA; 4. Taiho Pharmaceutical Co. Ltd, Tokyo, Japan; 5. Taiho Oncology, Inc., Princeton, USAShow moreShow less
Source PDF DOI Publisher page
88 days

A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer

Authors
Khobe Chandran; Christina Guo; Simon Pacey; Guillermo Villacampa; Ruth Matthews; Toby Prout; Joan Fernandes; Alison Turner; Mona Parmar; Ruth Riisnaes; Ana Ferreira; Suzanne Carreira; Claudia Bertan; Mateus Crespo; Ines Figueiredo; Wei Yuan; Denisa Bogdan; Florence Raynaud; Ruth Ruddle; Bianca Calì; Martino Maddalena; Arianna Calcinotto; Christina Yap; Adam Sharp; Andrea Alimonti; Johann De Bono; Alec PaschalisShow moreShow less
Affiliations
1. Institute of Cancer Research, London, UK; 2. The Royal Marsden NHS Foundation Trust, London, UK; 3. Department of Oncology, School of Clinical Medicine, University of Cambridge, Cambridge, UK; 4. Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital, Cambridge, UK; 5. Institute of Oncology Research (IOR), Bellinzona, Switzerland; 6. Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland; 7. Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; 8. Department of Health Sciences and Technology, Eidgenössische Technische Hochschule Zürich (ETH), Zurich, Switzerland; 9. Department of Medicine, University of Padova, Padua, ItalyShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does INVESTIGATIONAL NEW DRUGS take to review a manuscript?

As of 2026-11-19, CrushSCI has 16 complete review records for INVESTIGATIONAL NEW DRUGS. The fastest paper went from submission to acceptance in 25 days (Comparative efficacy of CLDN18.2-directed regimens in advanced gastric/gastroesophageal junction adenocarcinoma: a meta-analysis of single-arm trials, received 2026-08-12, accepted 2026-09-06); the slowest took 160 days. The average is 71 days and the median is 66 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.